Teleflex Valuation

Is TBH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TBH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€454.08
Fair Value
61.7% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: TBH (€174) is trading below our estimate of fair value (€454.08)

Significantly Below Fair Value: TBH is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TBH?

Key metric: As TBH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TBH. This is calculated by dividing TBH's market cap by their current earnings.
What is TBH's PE Ratio?
PE Ratio35.2x
EarningsUS$238.01m
Market CapUS$8.37b

Price to Earnings Ratio vs Peers

How does TBH's PE Ratio compare to its peers?

The above table shows the PE ratio for TBH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.4x
AFX Carl Zeiss Meditec
28.9x15.2%€5.2b
SHL Siemens Healthineers
31.7x13.8%€61.5b
DRW3 Drägerwerk KGaA
9.4x-0.7%€966.0m
EUZ Eckert & Ziegler
31.7x5.2%€1.1b
TBH Teleflex
35.2x19.4%€8.4b

Price-To-Earnings vs Peers: TBH is expensive based on its Price-To-Earnings Ratio (35.2x) compared to the peer average (25.4x).


Price to Earnings Ratio vs Industry

How does TBH's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
TBH 35.2xIndustry Avg. 32.3xNo. of Companies7PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TBH is expensive based on its Price-To-Earnings Ratio (35.2x) compared to the European Medical Equipment industry average (32.3x).


Price to Earnings Ratio vs Fair Ratio

What is TBH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TBH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.2x
Fair PE Ratio40.9x

Price-To-Earnings vs Fair Ratio: TBH is good value based on its Price-To-Earnings Ratio (35.2x) compared to the estimated Fair Price-To-Earnings Ratio (40.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TBH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€174.00
€229.69
+32.0%
10.0%€276.59€194.10n/a12
Jan ’26€170.00
€230.30
+35.5%
9.7%€275.00€192.98n/a12
Dec ’25€179.00
€229.25
+28.1%
8.4%€269.33€202.23n/a12
Nov ’25€183.00
€226.09
+23.5%
8.7%€263.00€197.48n/a13
Oct ’25€218.00
€233.48
+7.1%
6.3%€257.27€203.11n/a13
Sep ’25€216.00
€239.05
+10.7%
6.7%€265.73€206.17n/a14
Aug ’25€202.00
€235.27
+16.5%
7.7%€264.11€203.87n/a13
Jul ’25€193.00
€229.66
+19.0%
9.5%€265.42€195.57n/a14
Jun ’25€188.00
€227.79
+21.2%
10.9%€264.74€190.42n/a13
May ’25€192.00
€246.12
+28.2%
6.0%€268.21€211.75n/a14
Apr ’25€204.00
€242.28
+18.8%
5.5%€262.23€207.02n/a14
Mar ’25€204.00
€241.69
+18.5%
6.7%€263.37€194.99n/a14
Feb ’25€222.00
€242.12
+9.1%
7.4%€261.92€193.91€174.0014
Jan ’25€222.00
€228.82
+3.1%
9.1%€259.04€191.78€170.0014
Dec ’24€204.00
€223.52
+9.6%
8.9%€265.79€196.78€179.0014
Nov ’24€172.00
€233.40
+35.7%
12.6%€298.05€198.70€183.0014
Oct ’24€185.00
€243.57
+31.7%
12.2%€295.88€197.25€218.0014
Sep ’24€196.00
€239.96
+22.4%
10.4%€286.24€191.74€216.0014
Aug ’24€226.00
€244.49
+8.2%
10.9%€300.89€192.39€202.0014
Jul ’24€222.00
€243.43
+9.7%
10.6%€300.40€192.07€193.0014
Jun ’24€216.00
€253.10
+17.2%
10.6%€307.59€196.67€188.0015
May ’24€240.00
€241.92
+0.8%
10.8%€299.08€191.23€192.0014
Apr ’24€226.00
€246.52
+9.1%
11.1%€312.81€200.01€204.0015
Mar ’24€222.00
€246.52
+11.0%
11.1%€312.81€200.01€204.0015
Feb ’24€220.00
€237.33
+7.9%
12.8%€303.57€194.10€222.0015
Analyst Price Target
Consensus Narrative from 12 Analysts
€228.48
Fair Value
23.8% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 15:47
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Teleflex Incorporated is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Matthew TaylorBarclays
Craig BijouBofA Global Research